Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

IRLAB Therapeutics

0.65 SEK-69.65 %12/11 14:00
Less than 1K followers

IRLAB A

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-69.65 %
-62.02 %
-57.65 %
-47.53 %
-66.39 %
-71.46 %
-89.44 %
-98.49 %
-93.95 %

IRLAB Therapeutics is a Swedish research and pharmaceutical company. The research is based on the company's own research platform and specializes in the treatment of brain diseases, commonly referred to as neurodegenerative diseases. At the present, the company holds drug candidates specializing in, among other things, Parkinson's disease. The head office is located in Gothenburg.

Read more
Market cap
96.37M SEK
Turnover
32.22M SEK
Revenue
57.46M
EBIT %
-162.55 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
13/11
2026

Interim report Q3'26

12/2
2027

Annual report '26

All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release2026-11-12 12:05

Redeye: IRLAB: Deal timeline slips, cost savings announced

IRLAB Therapeutics
Regulatory press release2026-11-12 08:55

IRLAB stärker sitt fokus på intäktsgenerering, varslar personal och meddelar att sannolikheten för nya samarbetsavtal under 2026 har minskat

IRLAB Therapeutics
Regulatory press release2026-11-12 08:55

IRLAB strengthens focus on revenue generation, initiates workforce reductions, and announces reduced likelihood of new partnership agreements in 2026

IRLAB Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-11-06 07:00

IRLAB: Inbjudan till presentation och webcast av delårsrapport för det tredje kvartalet för 2026

IRLAB Therapeutics
Press release2026-11-06 07:00

IRLAB: Invitation to the interim report for Q3 2026 presentation and webcast

IRLAB Therapeutics
Press release2026-10-27 07:00

Det amerikanska patentverket avser att bevilja ett patent för IRLAB:s läkemedelskandidat IRL1117

IRLAB Therapeutics
Press release2026-10-27 07:00

The U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering IRLAB's drug candidate IRL1117

IRLAB Therapeutics
Regulatory press release2026-10-20 15:00

Valberedningen utsedd inför IRLAB:s årsstämma 2027

IRLAB Therapeutics
Regulatory press release2026-10-20 15:00

Nomination committee appointed for IRLAB’s annual general meeting 2027

IRLAB Therapeutics
Press release2026-10-20 07:00

IRLAB:s prekliniska forskning bakom linepemat publicerad i vetenskapligt granskad tidskrift

IRLAB Therapeutics
Press release2026-10-20 07:00

IRLAB’s Preclinical Research Underpinning Linepemat Published in Peer-Reviewed Journal

IRLAB Therapeutics
Press release2026-10-09 07:00

IRLAB to present at Redeye Theme: Neurology

IRLAB Therapeutics
Press release2026-10-09 07:00

IRLAB presenterar på Redeye Theme: Neurology

IRLAB Therapeutics
Regulatory press release2026-09-24 17:30

IRLAB utser Janne Backman till ny styrelseordförande

IRLAB Therapeutics
Regulatory press release2026-09-24 17:30

IRLAB Appoints Janne Backman as New Chairman of the Board

IRLAB Therapeutics
Regulatory press release2026-09-03 10:55

IRLAB’s CEO intends to step down during the first quarter of 2027

IRLAB Therapeutics
Regulatory press release2026-09-03 10:55

IRLAB:s vd avser att lämna sin position under det första kvartalet 2027

IRLAB Therapeutics
Regulatory press release2026-09-01 10:27

Finansinspektionen: Flaggningsmeddelande i IRLAB Therapeutics AB

IRLAB Therapeutics
Regulatory press release2026-08-31 07:00

Nytt antal aktier och röster i IRLAB Therapeutics AB

IRLAB Therapeutics
Regulatory press release2026-08-31 07:00

New number of shares and votes in IRLAB Therapeutics AB

IRLAB Therapeutics